| Regional market access pathways for diagnostics in Italy. |
| Author(s): Mantuano M1, Dionisi M2, Paolini D2, Gancitano G2, Urbinati D1 |
| Affiliations(s): 1 IMS Health, Milan, Italy 2 Roche Diagnostics, Italy. |
| Publication(s): ISPOR 19th Annual European Congress, 2016, 29 October-2 November, Vienna, Austria. |
| Document Type(s): Poster |
| Countries: Italy |
C:
Y: |
Health policy, Pricing and reimbursement, Regulatory
2016 |
|
L:
A: |
English
Review |
|
 |
| |
| |
| IMPACT OF POST-INSCRIPTION STUDIES ON REASSESSMENT IN FRANCE: A CASE STUDY ON ORPHAN DRUGS |
| Author(s): Jubert H, Ouali I, Kolahi C |
| Affiliations(s): IMS Health France |
| Publication(s): 19th ISPOR congress 2016 |
| Document Type(s): Abstract, Poster |
| Countries: France |
| Click here for the abstract |
C:
Y: |
Pricing and reimbursement
2016 |
|
L:
A: |
English
Clinical setting: Primary care, Literature Review, Pricing & Reimbursement, Review |
|
|
| |
| |
| COSTS EVOLUTION OF CANCER THERAPIES IN EUROPE FROM 2004 TO 2014 |
| Author(s): Tetafort A, Aubert JM, Perrot D, Brigot G, Kolahi C, Ansolabehere X |
| Affiliations(s): IMS Health France |
| Publication(s): 19th ISPOR Congress 2016 |
| Document Type(s): Abstract, Poster |
| Countries: France, Germany, Italy, UK |
| Click here for the abstract |
C:
Y: |
Oncology, Pricing and reimbursement
2016 |
|
L:
A: |
English
Clinical setting: hospital, Cost analysis, Pricing & Reimbursement, Retrospective database analysis |
|
|
| |
| |
| Quantification of patient preference analysis_Wearing the federal joint committee lens to assess evidence |
| Author(s): Gaba D1, Eheberg D, Bonduelle D |
| Affiliations(s): 1 Quintiles IMS, Gurgaon, India 2 QuintilesIMS, Munich, Germany |
| Publication(s): |
| Document Type(s): Poster |
| Countries: Germany, India |
C:
Y: |
Health status & patient reported outcomes, Pricing and reimbursement
2016 |
|
L:
A: |
English
Pricing & Reimbursement |
|
|
| |
| |
| Best supportive care or therapy according to physicians choice as appropriate comparator for german HTA dossiers-an underestimated chance or risk for the benefit assessment |
| Author(s): Bonduelle D1, Eheberg D1, Jakovac M1, Dannemann S1 |
| Affiliations(s): 1 QuintilesIMS, Munich, Germany |
| Publication(s): |
| Document Type(s): Poster |
| Countries: Germany |
C:
Y: |
Pricing and reimbursement
2016 |
|
L:
A: |
English
Pricing & Reimbursement |
|
|
| |
| |
| pCPA/CDR/pCODR Changes and Impact to Market Access in Canada |
| Author(s): Millson B, Zhang Y |
| Affiliations(s): IMS Brogan, A unit of IMS Health, Kirkland, QC, Canada |
| Publication(s): 2016 ISPOR Conference |
| Document Type(s): Poster |
| Countries: Canada |
| Click here for the abstract |
C:
Y: |
Pricing and reimbursement
2016 |
|
L:
A: |
English
Database Study |
|
|
| |
| |
| From centralized marketing authorization to national reimbursement - a challenging journey for new medical products with placebo controlled trials |
| Author(s): Eheberg D1, Paulus G1, Dannemann S1, Batscheider A1 |
| Affiliations(s): 1 IMS Health GmbH & Co. OHG, Munich, Germany |
| Publication(s): ISPOR 18th Annual European Congress, 7-11 November 2015, Milan, Italy |
| Document Type(s): Poster |
| Countries: Germany |
C:
Y: |
Pricing and reimbursement
2015 |
|
L:
A: |
English
Pricing & Reimbursement |
|
|
| |
| |
| DOES CONDITIONAL MARKETING AUTHORISATION INFLUENCE MARKET ACCESS IN FRANCE, ENGLAND, AND GERMANY? |
| Author(s): Kaaniche A1, Troubat A1, Sherwood A2 |
| Affiliations(s): 1IMS, PARIS, France, 2IMS Health, La Défense, France |
| Publication(s): ISPOR 18th Annual European Congress
Milan, Italy
November, 2015 |
| Document Type(s): Abstract, Poster |
| Countries: France, Germany, UK |
C:
Y: |
Health policy, Pricing and reimbursement
2015 |
|
L:
A: |
English
Market impact |
|
|
| |
| |
| Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database. |
| Author(s): Detournay B1, Halimi S2, Robert J1, Deschaseaux C3, Dejager S4. |
| Affiliations(s): 1Cemka-Eval, Bourg-la Reine, France.
2Department of Diabetology, Endocrinology and Nutrition, Grenoble University Hospital Center, Grenoble, France ; University Joseph Fourier, Grenoble, France.
3Novartis Pharma SAS, Market Access Department, Rueil-Malmaison, France.
4Novartis Pharma SAS, Medical and Scientific Affairs, Rueil Malmaison, France ; Department of Diabetology, Metabolism and Endocrinology, Pitié-Salpétrière Hospital, Paris, France. |
| Publication(s): Vasc Health Risk Manag. 2015 Jul 17;11:417-25. doi: 10.2147/VHRM.S84507. eCollection 2015. |
| Document Type(s): Article |
| Countries: France |
C:
Y: |
Diabetes, Pricing and reimbursement
2015 |
|
L:
A: |
English
Prospective study, Retrospective database analysis |
|
|
| |
| |
| First experiences with the new testing examination and treatment methods in Germany: Is this a new AMNOG clone? |
| Author(s): Bonduelle D1, Eheberg D1, Plantoer S1 |
| Affiliations(s): 1 IMS Health, Munich, Germany |
| Publication(s): ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
| Document Type(s): Poster |
| Countries: Germany |
C:
Y: |
Pricing and reimbursement
2014 |
|
L:
A: |
English
Pricing & Reimbursement |
|
|
| |
| |
 1 of 6 
|
